格隆汇8月7日丨光电股份(600184.SH)公布，公司于2025年8月7日召开第七届董事会第十七次会议、第 七届监事会第十一次会议，审议通过《关于使用暂时闲置募集资金进行现金管理的议案》，同意公司使 用不超过10亿元（含10亿元）的暂时闲置募集资金进行现金管理，使用期限自董事会审议通过之日起12 个月内有效。 ...

Group 1 - The company announced the approval of a proposal to use part of its temporarily idle raised funds for cash management, with a limit of up to RMB 200 million [2] - The investment will be made in low-risk, high-liquidity principal-protected financial products, specifically structured deposits from Ningbo Bank and Industrial and Commercial Bank of China [2] - The amounts invested are RMB 40 million and RMB 70 million, with investment periods of 21 days and 94 days, respectively, and expected annualized yields of 0.50%-1.90% and 0.80%-1.20% [2]

Core Viewpoint - The company, Shengda Biology, announced the use of idle raised funds for cash management, indicating a strategic move to enhance liquidity and yield on its financial resources [1] Group 1: Financial Management - Shengda Biology and its subsidiaries will utilize up to RMB 23,000.00 million of temporarily idle raised funds for cash management [1] - The total amount for this cash management initiative is RMB 5,000.00 million, which will be invested in structured deposit products from the Bank of China [1] - The expected annualized yield for the investment ranges from 0.60% to 1.80%, with a product duration of 32 days [1]

Core Viewpoint - The company has approved the use of idle raised funds and self-owned funds for cash management, aiming to enhance fund utilization efficiency and asset return rates while ensuring the safety of the principal [1][6]. Fundraising Basic Situation - In March 2019, the company issued convertible bonds totaling 1.2 billion yuan, with a net fundraising amount of approximately 1.187 billion yuan after deducting issuance costs [1]. Financial Products Basic Situation - The company plans to use up to 250 million yuan of idle raised funds for principal-protected financial products and up to 2.5 billion yuan of self-owned funds for both principal-protected and non-principal-protected financial products, trust products, and entrusted loan businesses [1][6]. Impact on the Company - The cash management using idle raised funds will not affect the normal operation of fundraising projects and is expected to create greater returns for shareholders [7]. Approval Process - The company held its annual shareholders' meeting on May 23, 2025, where the proposal for cash management was approved, allowing for rolling use of funds within the specified limits until the next annual meeting [1][6].

Group 1 - The company reported a total fundraising amount of RMB 184,569.50 million from the public offering of 44.05 million shares at a price of RMB 41.90 per share, with a net amount of RMB 169,114.64 million after deducting related expenses [2][3][4] - As of June 30, 2025, the company has utilized RMB 42,236.63 million of the raised funds for relevant projects [6][8] - The company has established a fundraising management system to ensure the proper storage and use of the raised funds, including signing tripartite supervision agreements with several banks [4][5][6] Group 2 - The company’s controlling shareholder, Zhongchumai Group, has completed a share buyback plan, acquiring 2,001,019 shares, which is approximately 1.1357% of the total share capital, with a total transaction amount of RMB 49,949,622.32 [51][52][53] - The buyback plan was initiated based on the controlling shareholder's confidence in the company's future development and was executed between March 28 and August 6, 2025 [52][53][54] - The company confirmed that the buyback does not affect its listing status or governance structure [57][58]

Group 1 - The company held its 16th meeting of the second supervisory board, with all three supervisors present, ensuring compliance with relevant laws and regulations [1] - The supervisory board approved the proposal to cancel the supervisory board and amend the company's articles of association, transferring the supervisory responsibilities to the audit committee of the board of directors [1][2] - The proposal to use part of the temporarily idle self-owned funds for cash management was also approved, allowing the company to invest up to RMB 4 billion in safe and liquid financial products [2][3] Group 2 - The supervisory board emphasized that it will continue to fulfill its supervisory duties until the shareholders' meeting approves the cancellation of the supervisory board, ensuring the protection of the company's and shareholders' interests [2] - The cash management proposal is aimed at improving the efficiency and return of fund usage while ensuring the company's normal operations and fund safety [3]

Core Viewpoint - Anxu Bio (688075.SH) plans to utilize up to RMB 4 billion of its temporarily idle self-owned funds to purchase low-risk, high-liquidity investment products through qualified financial institutions, with a usage period effective from September 18, 2025, for 12 months [1] Group 1 - The company intends to invest in safe and liquid financial products, including but not limited to principal-protected investment products, structured deposits, large-denomination certificates of deposit, and time deposits [1] - The investment will be executed through banks and securities companies that have legal operating qualifications [1] - The funds can be rolled over within the specified limit and duration [1]

Core Viewpoint - The company has approved the use of idle raised funds and self-owned funds for cash management, ensuring that it does not affect the normal operation of fundraising investment plans and the safety of raised funds [1] Group 1: Cash Management Approval - The company and its subsidiaries are authorized to use up to 100 million yuan of idle raised funds and up to 300 million yuan of self-owned funds for cash management within 12 months from the board's approval date [1] - The investment period for individual cash management products will not exceed 12 months [1] Group 2: Cash Management Implementation - The subsidiary, Hunan Hongong Intelligent Technology Co., Ltd., has utilized part of its idle self-owned funds for cash management [1] - The company has a total of 100 million yuan in unused self-owned funds for cash management as of the announcement date, which is within the authorized limit set by the board [3] Group 3: Risk Control Measures - The company will track and analyze the net value changes of cash management products and take necessary measures if risks to fund safety are identified [2] - Independent directors and the supervisory board have the authority to supervise and inspect the use of funds for related products [2] - The company will fulfill its information disclosure obligations according to the regulations of the Shenzhen Stock Exchange [2] Group 4: Impact on Company Operations - The use of idle self-owned funds for cash management will not affect the company's normal production and operation, as the purchased products are highly liquid and safe [3]

Core Viewpoint - The company has approved the use of idle self-owned funds and temporarily idle raised funds for cash management, ensuring that it does not affect the implementation of fundraising projects and the normal development of its main business [1][3]. Group 1: Cash Management Approval - The company plans to use up to RMB 20 billion of idle self-owned funds and up to RMB 17 billion of temporarily idle raised funds for cash management, focusing on high-security and high-liquidity deposit products or capital-protected products [1]. - The approved cash management will be valid for 12 months from the date of the board's approval, allowing for the funds to be used in a rolling manner within the specified limits [1]. Group 2: Special Settlement Account - The company has recently opened a special settlement account for cash management of raised funds, which will only be used for the settlement of temporarily idle raised funds [2]. - The account will be closed promptly when cash management products mature and there are no further purchase plans [2]. Group 3: Risk Control Measures - The company will strictly adhere to relevant regulations and internal policies when conducting cash management activities, with the finance department monitoring investment risks [3]. - The audit department and supervisory board have the authority to supervise and inspect the use of funds, and may hire professional institutions for auditing if necessary [3]. Group 4: Impact on the Company - The use of idle raised funds for cash management is expected to enhance fund utilization efficiency and generate investment returns, ultimately benefiting the company's performance and providing greater returns for shareholders [3].

Group 1 - The stock price of BGI Genomics is reported at 67.76 yuan, down 1.15% from the previous trading day, with an intraday high of 69.35 yuan and a low of 67.19 yuan, and a trading volume of 2.11 billion yuan [1] - BGI Genomics' main business includes the research, development, production, and sales of instruments and consumables related to life sciences and healthcare, covering products such as gene sequencers and laboratory automation equipment [1] - The company has recently opened a special settlement account for cash management of raised funds, planning to use up to 2 billion yuan of idle self-owned funds and 1.7 billion yuan of idle raised funds for cash management, focusing on purchasing safe and liquid deposit-type or capital-protected products [1]